Dr. Arthur Chou in their prestigious directory of accomplished individuals. Dr. Chou, a highly skilled neurosurgeon, is recognized for his expertise in surgeries for diseases of the brain and spine, as well as his dedication to providing exceptional care to his patients.
Industry: Health Services
Affiliations:
Press Releases By Arthur P. Chou M.D., Ph.D.
Los Angeles, CA - Dr. Chou, a highly skilled neurosurgeon, is recognized for his expertise in surgeries for diseases of the brain and spine, as well as his dedication to providing
Board Certified, American Board of Neurological Surgeons, 2020 to Present 2012 American Brain Tumor Association Basic Research Fellowship 2012 American Association of Neurological Surgeons
About:
Dr. Chou was initially from Taiwan and came to Los Angeles in 1988. He went on to receive his medical training at UCLA, completed his MD/PhD in 2008 and his neurosurgery residency in 2015. He is board certified by the American Board of Neurological Surgeons. His goals are to take care of his patients in the best way possible, to provide compassionate care and to obtain the best results.
Industry: Health Services
Current Organization: Arthur P Chou, MD, Ph.D.
Specialty: Brain and Spine Diseases , Neurosurgeons
Honors & Awards: UCLA Department of Neurosurgery Harold and Mimi Steinberg Resident Award
Affiliations: Primary Stroke Center at Garfield Medical Center, Allied Pacific IPA,
Website: https://www.drchou.la/
(2020 Present)
Medical Director
Monterey Park, California, United States of America
(2019 Present)
Neuroscience Director
Alhambra, California, United States of America
(2014)
Tumor Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas: Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, Cloughesy TF, Lai A. TumorSuppressive miR148a Is Silen
(2014)
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy: Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezare S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH
(2013)
Prediction of GBM outcome using combined analysis of MGMT protein expression and promoter methylation: Lalezari s·, Chou AP·, Tran A, Solis OE, Chen W, Carrillo JA, Selfridge J, Miller P, Mischel PS, Nghiemphu PL, Wang HJ, Elashoff RM, Liau LM, Cloughesy TF, Yong WH, Lai A. Prediction of GBM o
(2013)
Overexpression of isocitrate dehydrogenase 1 (IDH1) R132H mutant protein renders U87 glioma cells less malignant and more sensitive to radiation: Lis·, Chou AP·, Chen W, Chen R, Deng Y, Phillips HS, Faull KF, Cloughesy TF, Liau LM, Lai A. Overexpression of isocitrate dehydrogenase 1 (IDH1) R132H mutant protein renders U87 glioma ce
(2012)
Identification of Retinal Binding Protein 1 (RBP1) Promoter Hypermethylation in IDH1/IDH2 Mutant Gliomas: Chou AP·, Chowdhury R·, Lis·, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum
(2012)
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy: Pope WB, Prins RB, Thomas MA, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu
(2010)
Mechanisms of rotenone-induced proteasome inhibition: Chou AP, Li S, Fitzmaurice AG, Bronstein JM. Mechanisms of rotenone-induced proteasome inhibition. Neurotoxicology. 31, 367-372, 2010. doi:10.1016/j.neuro.2010.04.006
(2010)
In Silica Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays: Tran A, Escovedo C, Migdall-Wilson J, Chou AP, Chen W, Cloughesy T, Nelson S, Lai A. In Silica Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Ag
(2008)
Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome: Chou, AP, Maidment N, Klintenberg R, Casida JE, Li S, Fitzmaurice AG, Fernagut PO, Chesselet M-F, Bronstein JM. Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome
(2006)
Inhibitory effects of pesticides on proteasome activity: Implication in Parkinson's disease: Wang XF, Li S, Chou AP, Bronstein JM. Inhibitory effects of pesticides on proteasome activity: Implication in Parkinson's disease. Neurobiol Dis, 23(1 ): 198-205, 2006. doi:10.1016/j.nbd.2006
(2001)
Thermal Chemistry of C3Metallacycles on Pt(111) Surfaces: Chrysostomou D, Chou A, Zaera F. Thermal Chemistry of C3Metallacycles on Pt(111) Surfaces. J. Phys. Chem. B, 105: 5968-5978, 2001. doi:10.1021/jp0105387
(1999)
Ab initio study of the intermolecular potential surface of He-NH3: Li ZR, Chou A, Tao F-M. Ab initio study of the intermolecular potential surface of He-NH3. Chem. Phys. Ltrs., 313(1-2): 313-320, 1999. doi:10.1016/S0009-2614(99)01083-0
(1999)
Density functional studies of the formation of nitrous acid from the reaction of nitrogen dioxide and water vapor: Chou A, Li ZR, Tao F-M. Density functional studies of the formation of nitrous acid from the reaction of nitrogen dioxide and water vapor. J. Phys. Chem. A, 103(39): 7848-7855, 1999. doi: 10.
(2011)
Academic Excellence
(2012)
(2012)
( 2020)
Education Level: Master's
Institute Name: Board Certification from the American Board of Neurological Surgery
Location: United States of America
Education Level: Residency
Institute Name: UCLA Medical Center
Location: United States of America
Education Level: M.D.
Institute Name: UCLA David Geffen School of Medicine
Location: United States of America
Education Level: Ph.D.
Institute Name: UCLA David Geffen School of Medicine
Location: United States of America
Date of Birth
1978-06-04
Gender
Place of Birth
, ,Taiwan
Marital Status
Married